Which statement about MAT medications is true?

• A. It includes methadone, buprenorphine, and naltrexone.
• B. It relies solely on psychosocial therapy.
• C. It uses disulfiram as the primary agent.
• D. It excludes any opioid receptor agonists.

Answer: (A)

Medications used in MAT for opioid use disorder include methadone, buprenorphine, and naltrexone. Methadone is a full opioid agonist that satisfies receptors to prevent withdrawal and reduce cravings, typically provided in a supervised clinic setting. Buprenorphine is a partial agonist with a ceiling effect, which lowers overdose risk while easing withdrawal and cravings; it can be prescribed by trained clinicians and often comes with formulations that deter misuse. Naltrexone is an opioid antagonist that blocks opioid effects, used after detox to prevent relapse, with options for daily oral dosing or monthly extended-release injections.

This statement is true because MAT encompasses these three medications, each with different mechanisms that support recovery. It is not accurate to say MAT relies solely on psychosocial therapy, uses disulfiram as the primary agent, or excludes any opioid receptor agonists, since methadone and buprenorphine are opioid receptor agonists/partial agonists and naltrexone is an antagonist.